Invivyd posts CANOPY older-adult subgroup analysis presentation on pemivibart for COVID-19 prevention
PUBT · 06/16 18:27
Share
Listen to the news
- Invivyd published a CANOPY Phase 3 subgroup analysis of pemivibart for COVID-19 pre-exposure prevention in adults aged 65+.
- Older-adult enrollment totaled 95 in Cohort A (immunocompromised) plus 88 in Cohort B (non-immunocompromised; 61 pemivibart, 27 placebo).
- No RT-PCR-confirmed symptomatic COVID-19 cases occurred in the Cohort A older-adult subgroup through Month 6.
- Cohort B older-adult subgroup reported 3 symptomatic cases through Month 6; 1 on pemivibart, 2 on placebo; estimated sRRR 77.9%.
- Older-adult safety through Month 6 showed TEAEs of 63.2% in Cohort A plus 37.5% in Cohort B; no anaphylaxis reported in either subgroup.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved